Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer – European Pharmaceutical Review

We


European Pharmaceutical Review

Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer
European Pharmaceutical Review
TG02 is the second TG cancer immune activator to enter the clinic from the company’s peptide-based immunotherapy platform. It contains a proprietary mixture of eight synthetic peptides representing fragments of the most frequent RAS mutations seen in …

and more »


Source link

We